An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of an article in the prestigious international journal “Pharmaceutics.” The article titled “Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs” is about the importance of precision medicine in oncology. In particular, the study […]
Search
New drug BGA002 overcomes Neuroblastoma resistance to Retinoic Acid drug
An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Journal of Experimental & Clinical Cancer Research.” The article titled “The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified Neuroblastoma” is […]
Corporate Update
INTEGRAE SIM is chosen as Listing Sponsor and Global Coordinator.
BIOGENERA has chosen INTEGRAE SIM (a leading Italian company in extraordinary finance for SMEs with more than 60 successfully completed IPOs) as Listing Sponsor and Global Coordinator for the path of preparing the IPO on Euronext Paris. INTEGRAE SIM develops a wide range of investment banking services focused mainly on small- and mid-capitalization companies to […]
Corporate Update
BIOGENERA closes at more than 2.8 million raised on CrowdFundMe
BIOGENERA SpA’s crowdfunding campaign conducted on the CrowdFundMe digital platform, which ended in October 2021, recorded an average investment of about 4,400 euros, thus totaling for BIOGENERA a collection of more than 2.8 million euros from 644 investors. campaign link: equity crowdfunding campaign conducted on CrowdFundMe The more than 2.8 million euros raised in less […]
Corporate Update
BIOGENERA chooses Gitti & Partners as legal advisor
BIOGENERA SpA has chosen the law firm Gitti and Partners as the company’s Legal Advisors for the preparation of the company’s path to listing on the Euronext Paris Stock Exchange. The firm Gitti and Partners can boast many years of experience in stock market listings. Its professionals have developed specialized expertise and operational skills in […]
Search
New anti-tumor drug BGA002 fights Neuroblastoma through the mitochondrial pathway
An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Cancer Research.” The article titled “A Novel MYCN-Specific Antigen Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. The article is about the anti-tumor effects obtained in preclinical studies of BIOGENERA’s […]
